MXPA05007791A - Formulaciones mejoradas para el suministro vaginal transmucosal de bisfosfonatos. - Google Patents

Formulaciones mejoradas para el suministro vaginal transmucosal de bisfosfonatos.

Info

Publication number
MXPA05007791A
MXPA05007791A MXPA05007791A MXPA05007791A MXPA05007791A MX PA05007791 A MXPA05007791 A MX PA05007791A MX PA05007791 A MXPA05007791 A MX PA05007791A MX PA05007791 A MXPA05007791 A MX PA05007791A MX PA05007791 A MXPA05007791 A MX PA05007791A
Authority
MX
Mexico
Prior art keywords
bisphosphonates
delivery
transmucosal
vaginal delivery
improved formulations
Prior art date
Application number
MXPA05007791A
Other languages
English (en)
Inventor
E Clendening Chris
Original Assignee
Umd Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umd Inc filed Critical Umd Inc
Publication of MXPA05007791A publication Critical patent/MXPA05007791A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/08—Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception, e.g. combined with devices protecting against contagion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/08—Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception, e.g. combined with devices protecting against contagion
    • A61F6/12—Inserters or removers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Dispositivos, metodos y formulacion mejorada para el suministro vaginal transmucosal de bisfosfonatos. El suministro de bisfosfonatos dirigido al sitio hacia la circulacion sistemica utilizando un dispositivo vaginal que comprenden una formulacion mejorada de bisfosfonato para el suministro transmucosal. Un metodo para le tratamiento de la osteoporosis y enfermedades oseas y del esqueleto relacionadas, para la prevencion de fracturas oseas y perdida de la masa osea y la dureza mediante la administracion intravaginal de bisfosfonatos hacia la vagina y el suministro transmucosal de bisfosfonatos hacia la circulacion vaginal.
MXPA05007791A 2003-01-22 2004-01-14 Formulaciones mejoradas para el suministro vaginal transmucosal de bisfosfonatos. MXPA05007791A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/349,029 US6905701B2 (en) 1997-06-11 2003-01-22 Formulations for transmucosal vaginal delivery of bisphosphonates
PCT/US2004/000902 WO2004067063A2 (en) 2003-01-22 2004-01-14 Improved formulations for transmucosal vaginal delivery of bisphosphonates

Publications (1)

Publication Number Publication Date
MXPA05007791A true MXPA05007791A (es) 2005-09-30

Family

ID=32823695

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05007791A MXPA05007791A (es) 2003-01-22 2004-01-14 Formulaciones mejoradas para el suministro vaginal transmucosal de bisfosfonatos.

Country Status (12)

Country Link
US (1) US6905701B2 (es)
EP (1) EP1587470A2 (es)
JP (1) JP2006515889A (es)
CN (1) CN1741779A (es)
AU (1) AU2004207456A1 (es)
BR (1) BRPI0406635A (es)
CA (1) CA2514109A1 (es)
IL (1) IL169694A0 (es)
MX (1) MXPA05007791A (es)
NO (1) NO20053657L (es)
NZ (1) NZ541776A (es)
WO (1) WO2004067063A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050163826A1 (en) * 1997-06-11 2005-07-28 Umd, Inc. Medicated tampon
US8178123B2 (en) * 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
WO2003095029A1 (en) 2002-05-10 2003-11-20 F. Hoffmann-La Roche Ag Bisphosphonic acid for the treatment and prevention of osteoporosis
AU2003286796A1 (en) * 2002-10-31 2004-06-07 Umd, Inc. Therapeutic compositions for drug delivery to and through covering epithelia
RU2315603C2 (ru) 2002-12-20 2008-01-27 Ф.Хоффманн-Ля Рош Аг Композиция с высокой дозой ибандроната
DE602004026173D1 (de) 2003-04-29 2010-05-06 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
US20050244402A1 (en) * 2004-04-30 2005-11-03 Villanueva Julie M Absorption of pain-causing agents
US20060100566A1 (en) * 2004-11-05 2006-05-11 Women's Medical Research Group, Llc Apparatus and method for the treatment of dysmenorrhea
EP2316441A1 (en) * 2005-02-17 2011-05-04 Hadasit Medical Research Services And Development Bisphosphonates for treating endometriosis
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US20070172507A1 (en) * 2006-01-26 2007-07-26 Paul Zupkas Transluminal drug delivery methods and devices
WO2008039864A1 (en) * 2006-09-26 2008-04-03 Novavax, Inc. Emulsion formulations for transdermal delivery of poorly water soluble active agents
EP2181721A3 (de) * 2006-11-06 2010-05-19 Lohmann & Rauscher GmbH & Co. KG Produkt zur Versorgung von Entzündungen, Druckstellen und/oder Aphten im Oralbereich sowie Verwendung eines solchen Produkts
AR064262A1 (es) * 2006-11-17 2009-03-25 Besins Healthcare Composiciones farmaceuticas liquidas que comprenden un compuesto bisfosfonato
US20080254098A1 (en) * 2007-04-11 2008-10-16 Ehrlich Shelley R Neural tube birth defect reduction with folic acid delivery in catamenial hygiene products
US20090215729A1 (en) * 2008-02-19 2009-08-27 Johnson Erin M Microparticle compositions to modify cancer promoting cells
US8323687B2 (en) * 2008-03-18 2012-12-04 Aleksander Vladimirovich Dikovskiy Pharmaceutical composition for the prevention and treatment of bone tissue resorption of various etiology
CA2860108C (en) * 2011-12-29 2016-10-04 Laboratorios Andromaco S.A. Vaginal ring including meloxicam and an agent for modulating the release of the active principle, which can be used as a continuous-use contraceptive in women
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
EP3272333A1 (en) 2016-07-22 2018-01-24 Chemo Research, S.L. Vaginal composition comprising a combination of estrogen and vitamin d
ES2968763T3 (es) * 2018-03-29 2024-05-13 The Materia Company Ltd Formulación intravaginal
GB201808567D0 (en) * 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Pharmaceutical compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197327B1 (en) * 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
US6572874B1 (en) * 1998-05-15 2003-06-03 Umd, Inc. Vaginal delivery of bisphosphonates
US6416779B1 (en) * 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections

Also Published As

Publication number Publication date
BRPI0406635A (pt) 2005-12-06
NZ541776A (en) 2008-01-31
WO2004067063A3 (en) 2004-11-04
CA2514109A1 (en) 2004-08-12
US6905701B2 (en) 2005-06-14
NO20053657D0 (no) 2005-07-27
JP2006515889A (ja) 2006-06-08
NO20053657L (no) 2005-10-19
CN1741779A (zh) 2006-03-01
AU2004207456A1 (en) 2004-08-12
WO2004067063A2 (en) 2004-08-12
US20040005345A1 (en) 2004-01-08
EP1587470A2 (en) 2005-10-26
IL169694A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
MXPA05007791A (es) Formulaciones mejoradas para el suministro vaginal transmucosal de bisfosfonatos.
BR0113134A (pt) Aplicação vaginal de bisfosfonatos
DE60141145D1 (es)
WO2003082188A3 (en) Methods and drug delivery systems for the treatment of orofacial diseases
AU2003301190A8 (en) Administration of capsaicinoids
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
EP1292709A4 (en) CONJUGATE ADDITION REACTIONS FOR REGULATED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS
CY1109661T1 (el) 5-cnac ως παραγοντας για χορηγηση απο το στομα τμηματων παραθορμονης
WO2006102359A3 (en) Delivery of highly lipophilic agents via medical devices
BR0112571A (pt) Método para o tratamento de fêmeas humanas, composição farmaceuticamente aceitável e dispositivo para aplicação intravaginal ou transvaginal de um agente farmacêutico antifúngico, antiviral, antibacteriano ou parasiticida
EP2049023A4 (en) APPARATUS AND METHOD FOR MANIPULATING OR RETRACTING ANATOMIC FABRICS AND STRUCTURES
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
SE0100568D0 (sv) Compounds
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
EP2407203A3 (en) Solid therapeutic agent for use in an implantable drug delivery device
MXPA05010196A (es) Nuevas formulaciones y su uso.
HUP0301791A2 (hu) Eljárás klimaktériummal összefüggő rendellenességek kezelésére nőkben a menopauza alatt vagy után
MY149482A (en) Vaginal formulation of lidocaine for treating uterine dysrhythmia
NZ617397A (en) Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units
ATE415953T1 (de) Vorrichtung zur wirkstofffreisetzung mit einer netzhülse
GB2411116A (en) Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative
SE0100566D0 (sv) Compounds
WO2002062352A3 (en) Devices and methods for management of bone density
WO2009073918A3 (en) Agent delivery device and method
GEP201606538B (en) Preoperative treatment of post operative pain